How Long Does Vulvar Cancer Take to Develop?

Vulvar cancer does not appear overnight. In most cases, it develops over years from precancerous changes in the skin of the vulva, and the timeline depends heavily on which biological pathway is driving the process. Untreated precancerous lesions have been documented progressing to invasive cancer in as few as one to two years or taking well over a decade, with the average sitting somewhere around four to seven years depending on the type. That wide range is not vagueness for its own sake; it reflects genuinely different diseases traveling under the same umbrella, and understanding which pathway is involved changes everything about risk and urgency.

Two Distinct Pathways, Two Different Clocks

Vulvar squamous cell carcinoma, which accounts for the vast majority of vulvar cancers, develops along one of two routes. The first is driven by persistent infection with high-risk strains of human papillomavirus (HPV), particularly HPV 16 and 18. This pathway tends to produce precancerous changes classified as high-grade squamous intraepithelial lesions (HSIL, formerly called usual VIN or uVIN). The second pathway is HPV-independent, typically linked to chronic inflammatory skin conditions like lichen sclerosus, and gives rise to a precursor called differentiated VIN (dVIN). These two pathways behave very differently in terms of how quickly they can become cancer.

For HPV-associated HSIL, progression to invasive cancer is relatively slow. A study tracking over 400 women with vulvar precancerous lesions found that among ten untreated cases, progression to invasion took between 1.1 and 7.3 years, with a mean of about 3.9 years.¹ A large population-based study found the ten-year cumulative risk of developing vulvar squamous cell carcinoma was about 10% for women with HSIL alone.² That is not a trivial risk, but it means the majority of HPV-associated precancerous lesions do not become cancer within a decade, especially if they are treated.

The HPV-independent pathway is a different story. Differentiated VIN, though much less common, is far more dangerous. A Dutch population study found the ten-year cumulative cancer incidence for dVIN was 50%, compared to under 10% for HSIL.² A separate analysis put the ten-year cancer risk for HPV-independent VIN with p53 mutations at roughly 67%.³ Differentiated VIN also tends to progress faster than HSIL, sometimes within one to two years of appearing.⁴ The combination of higher risk and shorter timeline makes dVIN the more urgent clinical concern, even though it accounts for a smaller share of precancerous diagnoses.

Why Lichen Sclerosus Changes the Equation

Lichen sclerosus is a chronic inflammatory skin condition that most commonly affects the vulva, causing itching, thinning skin, and whitish patches. It is not cancer, and most women who have it will never develop vulvar cancer. But its presence substantially raises the odds. A large cohort study found that women with lichen sclerosus had a standardized incidence ratio for vulvar cancer of about 34, meaning they were roughly 34 times more likely to develop it than the general population.⁵

Among women with vulvar precancerous lesions, the presence of lichen sclerosus dramatically increased cancer risk. In one study, the ten-year cumulative cancer incidence for women with HSIL and co-existing lichen sclerosus was about 38%, compared to roughly 8% for those with HSIL alone. Even after adjusting for other factors, lichen sclerosus independently tripled the risk of progressing to invasive cancer.² A retrospective analysis found that women with lichen sclerosus who eventually developed vulvar cancer were diagnosed with the cancer at a mean age of about 68, while those who never developed cancer had a mean onset of lichen sclerosus around age 53.⁶ That gap of roughly fifteen years gives a rough sense of the timeline from inflammatory disease to malignancy in the subset that does progress, though it varies widely among individuals.

Lichen sclerosus is most closely linked to the HPV-independent, differentiated VIN pathway. The chronic inflammation it causes appears to create a microenvironment where genetic changes, particularly TP53 mutations, accumulate in the vulvar skin over time. One study found TP53 mutations in about 44% of vulvar cancers, and these mutations were significantly associated with HPV-negative tumors.⁷ In practical terms, if you have lichen sclerosus, consistent follow-up with a gynecologist or dermatologist is genuinely important for catching changes early.

Diagnostic Delays Often Add Years

One of the more frustrating aspects of vulvar cancer is that the timeline from the first symptoms a woman notices to the actual cancer diagnosis can be very long, not because the cancer is slow but because it is frequently misdiagnosed or dismissed. The most common early symptom is persistent vulvar itching, which is so widespread in the general population that neither patients nor clinicians always take it seriously.⁸

A study of German gynecological practices found that the mean delay between an initial diagnosis of vulvar inflammation and the eventual detection of vulvar cancer was about 328 days, nearly a full year. For women first diagnosed with noninflammatory vulvar disorders like atrophy or cysts, the delay averaged around 300 days.⁹ In a South African cohort, the picture was even starker: over 73% of women had more than twelve months between symptom onset and cancer diagnosis, and nearly 95% had been treated multiple times for their symptoms before anyone performed a biopsy.¹⁰

These delays matter because vulvar cancer caught at an early stage is far more treatable than cancer that has spread to lymph nodes. The development timeline from precancer to invasion may be years, but the window between “this is still easily treatable” and “this has become a much bigger problem” can be narrower. If you have persistent vulvar itching, a sore that will not heal, a lump, or changes in skin color or texture that do not resolve with basic treatment, pushing for a biopsy rather than accepting another course of topical cream is reasonable and could be consequential.

What Speeds Up Progression

Several factors appear to compress the timeline from precancerous changes to invasive cancer. Age is one of the strongest independent predictors. Women who are 50 or older at the time their precancerous lesion is diagnosed have roughly double the cancer risk compared to younger women.² This tracks with the broader epidemiology: the median age at diagnosis for HPV-associated vulvar cancers is 67, and for non-HPV-associated cancers it is 71.¹¹

Smoking is another well-documented accelerant. It is a recognized risk factor both for developing vulvar precancerous lesions in the first place and for recurrence after treatment.¹² Smoking suppresses local immune function in ways that allow HPV infections to persist longer and precancerous cells to accumulate genetic damage more freely.

Immunosuppression, whether from HIV, organ transplant medications, or other causes, is one of the most potent risk factors. A study of immunocompromised women found they had a 2.3-fold increased risk of recurrence after treating vulvar condylomas, along with dramatically higher odds of progressing to precancerous lesions and invasive disease.¹³ Researchers have described the progression in immunosuppressed patients as essentially an accelerated version of what happens over many years in women with healthy immune systems.¹⁴

Treating Precancerous Lesions to Reset the Clock

Because vulvar cancer almost always passes through a recognizable precancerous stage, treating that stage effectively can prevent cancer from ever developing. For HPV-associated HSIL, two main approaches exist: surgical excision and topical immunotherapy.

Surgical excision, typically a wide local excision that removes the affected tissue with clear margins, remains the standard of care. It provides tissue for microscopic examination, which is important because occasionally what appears to be a precancerous lesion on biopsy turns out to harbor early invasion. The drawback is that vulvar surgery can cause significant scarring and sexual dysfunction, particularly when lesions are multifocal (appearing in several spots at once).

Topical imiquimod has emerged as a nonsurgical alternative for HPV-associated HSIL. A randomized trial published in the New England Journal of Medicine found that imiquimod cream applied three times per week for 16 weeks shrank lesions by more than 25% in about 81% of treated women, compared to none in the placebo group. HPV cleared from the lesion in 58% of the imiquimod group. About a third of women treated with imiquimod had a complete response that lasted at least a year.¹⁵ The drug works by activating immune cells in the skin to attack HPV-infected abnormal cells.¹⁶

Differentiated VIN, by contrast, is almost always treated surgically. Its rapid progression and high cancer risk make watchful waiting or topical therapies too risky. Complete excision with clear margins is the goal, and close follow-up afterward is essential because recurrence rates are high.

Recurrence Is Common and Can Happen Late

Even after successful treatment of vulvar cancer itself, recurrence is a persistent concern that extends far beyond the typical five-year surveillance window used for many cancers. A study tracking recurrence patterns found that the cumulative recurrence rate was about 19% at one year, 35% at three years, 42% at five years, and reached nearly 57% at ten years after diagnosis.¹⁷ While most recurrences happen in the first three years, a meaningful proportion appear after the five-year mark, which means that long-term follow-up remains important.

Part of the reason for late recurrences relates to a concept called field cancerization. When the vulvar skin has been exposed to chronic HPV infection or long-standing inflammation from lichen sclerosus, the entire field of tissue can harbor genetic abnormalities even if a particular lesion has been completely removed. A new cancer arising in that same field years later may look like a recurrence but is actually a second primary cancer developing from the same underlying soil of damaged tissue. This is why smoking cessation, control of lichen sclerosus, and ongoing examination matter even years after treatment.

HPV Vaccination and Primary Prevention

Because roughly half of vulvar cancers are driven by HPV, vaccination represents a major opportunity to prevent the disease before it starts. A systematic review found that the quadrivalent HPV vaccine showed 100% efficacy against HPV 16/18-related vulvar and vaginal precancerous lesions and cancers in per-protocol analyses, with about 71% efficacy in broader intention-to-treat populations that included women who may have already been exposed.¹⁸ The newer nine-valent vaccine extends protection to additional HPV types. Long-term follow-up data from one bivalent vaccine trial showed durable protection against high-grade cervical, vulvar, and vaginal lesions for at least ten years, with vaccine efficacy around 88%.¹⁹

There is also early evidence that vaccination may help after treatment for vulvar precancerous lesions, not just before HPV exposure. One study found that women vaccinated after surgical treatment for vulvar HSIL had a recurrence rate of 19% compared to 32% in unvaccinated women. The difference was not statistically significant in that particular study, but the trend was encouraging enough that researchers continue to investigate this use.²⁰ Vaccination is most effective before any HPV exposure, which is why routine immunization in adolescence remains the strongest public health tool against HPV-associated vulvar cancer.

Non-Squamous Vulvar Cancers Follow Different Rules

Squamous cell carcinoma makes up about 90% of vulvar cancers, but the remaining fraction includes types that develop on entirely different timelines and from different precursors.

Vulvar Paget’s disease is a rare condition where abnormal cells spread within the surface layer of vulvar skin, often presenting as a red, scaly, or weeping patch that is frequently mistaken for eczema or a fungal infection. It can remain in situ (noninvasive) for many years. One documented case showed progression from in situ Paget’s disease to invasive carcinoma with lymph node involvement after an interval of nearly eleven years.²¹ While many cases of vulvar Paget’s disease never become invasive, this example established that the potential is real, and the long latency can foster complacency.

Vulvar melanoma, the second most common type of vulvar cancer, does not arise from a squamous precursor at all. Up to 10% of women have pigmented vulvar lesions, the vast majority of which are benign. But vulvar melanomas are often diagnosed at advanced stages with larger tumor sizes than cutaneous melanomas elsewhere on the body, likely because the vulva is not a site most women routinely inspect.²² The median age at diagnosis is about 68. Unlike squamous cell carcinoma, melanoma does not follow a well-characterized years-long precancerous progression, and it can grow aggressively once it begins. Any new or changing pigmented lesion on the vulva warrants prompt evaluation.

How Terminology Has Complicated the Picture

Part of the confusion around vulvar cancer timelines stems from decades of shifting classification systems. The terminology for vulvar precancerous lesions has changed repeatedly over nearly a century, and each change has had real consequences for how clinicians think about these lesions and how aggressively they treat them.²³

A significant concern raised by the 2015 International Society for the Study of Vulvovaginal Disease was that standardized terminology systems designed primarily around cervical disease risked obscuring differentiated VIN. Because dVIN does not fit neatly into the HPV-centric framework that works for cervical precancers, there was worry that clinicians unfamiliar with the term might overlook it entirely, despite its high malignant potential.²⁴ Given that dVIN is the precursor with the fastest progression to cancer, this is not an academic concern. If the most dangerous precursor gets missed because it does not match the expected pattern, patients lose time they may not have much of.

The same terminology update also warned against including the term “low-grade squamous intraepithelial lesion” for vulvar lesions, since doing so could lead to overdiagnosis and overtreatment of benign, self-resolving HPV effects like genital warts. In vulvar pathology, low-grade HPV changes are overwhelmingly harmless, while the high-grade and differentiated lesions are the ones that matter. Getting the diagnostic labeling right has direct implications for whether a woman ends up with unnecessary surgery or, worse, with a dangerous lesion that was not biopsied.

Emerging Research on the Vulvar Microbiome

A newer area of investigation involves the bacterial communities living on vulvar skin and how they differ between healthy tissue, precancerous lesions, and cancerous tissue. Research has found that the vulvar skin of women with HPV-associated precancerous lesions shows an increase in certain anaerobic bacteria, including species from the Prevotella and Fusobacteria groups, compared to unaffected skin. Women with differentiated VIN showed a different pattern, including depletion of protective Lactobacillus species and enrichment of other anaerobic taxa.²⁵

This research is still in early stages, and nobody is suggesting that bacteria cause vulvar cancer. But chronic inflammation and altered microbial communities could theoretically create an environment that makes progression more likely, or these microbial shifts could simply be markers of tissue damage already underway. Either way, it adds to the picture of vulvar cancer development as a process shaped not just by viruses and genes but by the broader tissue environment over time. Whether microbiome-targeted interventions could ever play a role in prevention remains speculative, but the field is moving in that direction for several cancer types.